Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

Desde: GRACEcast
0 0 hace 7 años
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Síguenos en Facebook